Our lab has validated this pathway pharmacologically, demonstrating that applying neuroserpin or blocking plasmin activity compromises the conversion of proNGF to mature NGF leading (as in the AD pathology) to increased proNGF brain levels, atrophy of BFCNs, and loss of cholinergic synapses [91,102,103]. This evidence concerns the gene NGF and Alzheimer disease.